1. Home
  2. |Insights
  3. |Inclusion of Deferred Compensation Found Proper Where Government Forced Contractor’s Hand

Inclusion of Deferred Compensation Found Proper Where Government Forced Contractor’s Hand

Client Alert | 1 min read | 08.11.17

In Quimba Software, Inc. v. United States (No. 12-142C), the Court of Federal Claims granted Quimba’s Motion for Summary Judgment, finding that “Quimba’s inclusion of deferred compensations costs in its 2004 [Incurred Cost Proposal] [wa]s allowable under the FAR….” Specifically, while the government argued that the FAR and CAS requirements precluded “deferred compensation for closely held companies ‘except in the year in which the compensation [wa]s paid,’” the Court found that Quimba’s situation fell within the “limited exception” to the IRS deductibility-timing rules because “Quimba’s deferral of its FY 2004 compensation was unintended, unavoidable, and unanticipated[,]” and “Quimba’s financial difficulty, which forced payment of the compensation beyond 2004, was unforeseeable through FY 2004.” In this respect, the Court recognized that the government effectively “forced Quimba’s hand” to defer compensation when it failed to make additional payments beyond the first payment as a result of the government’s “updating and approval process” of Quimba’s accounting system, which took “the entirety of FY 2004 and continue[d] through a significant part of FY 2005.”

Insights

Client Alert | 6 min read | 04.29.26

CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)

On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies....